Efficacy of Yupingfeng powder in the treatment of bronchial asthma in adults: a systematic review and meta‐analysis

Background: Yupingfeng Powder (YPF), a classical Chinese herbal formula composed of Astragalus membranaceus, Atractylodes macrocephala, and Saposhnikovia divaricata, has demonstrated potential efficacy in the treatment of adult bronchial asthma when combined with conventional biomedical therapy (CBT), as indicated by multiple recent clinical studies. However, existing research is limited by small sample sizes, inconsistent methodological quality, and non-uniform syndrome differentiation, resulting in insufficient evidence strength. Moreover, traditional meta-analysis methods struggle to address study heterogeneity, and its definitive efficacy remains inadequately validated. Objective: To systematically evaluate the clinical efficacy and safety of YPF combined with CBT in the treatment of adult bronchial asthma, and to clarify the heterogeneity sources. Methods: Strictly adhering to the PRISMA 2020 guidelines, the study protocol was registered in PROSPERO (registration number: CRD420251172600). A systematic search was conducted in seven databases (PubMed, Embase, Cochrane Library, China, etc., up to 20 October 2025), and randomized controlled trials (RCTs) comparing YPF+CBT with CBT alone in adults with bronchial asthma were included. The Cochrane ROB 2.0 tool was used to assess the risk of bias, and meta-analysis was performed using RevMan 5.4 and Stata 18 software. Subgroup analysis and Meta regression were employed to explore the sources of heterogeneity. Results: = 0.0%]. Significant improvements were observed in pulmonary function parameters (FEV1, FVC, FEV1/FVC, PEF) and asthma control test (ACT) scores [SMD were 1.32, 1.78, 1.09, 1.15, and 1.80, respectively, all P < 0.05]. No statistically significant difference was found in the CD4+/CD8+T lymphocyte subset ratio between the two groups [SMD = 0.50, 95%CI(-0.44, 1.44), P = 0.301]. Subgroup analysis and meta-regression confirmed that treatment duration (P = 0.03) and study year (P = 0.043) were the primary sources of heterogeneity. In terms of safety, only two studies reported mild adverse events (e.g., gastrointestinal discomfort, dry mouth), with no significant difference in incidence between the groups and no serious adverse events. Clinical significance analysis showed that the clinical overall response rate in the YPF+CBT group was 86.8%, which was compared to 72.3% in the CBT group, with an absolute risk reduction (ARR) of 14.5%, indicating clear clinical benefits of this combination therapy. Conclusion: YPF combined with CBT can significantly improve clinical efficacy, pulmonary function, and symptom control in adult bronchial asthma patients. However, due to limitations such as moderate methodological quality of the included studies, geographical constraints, and insufficient adverse event data, the conclusions require further validation through high-quality RCTs with large sample sizes, double-blind design, and placebo control. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=1172600, identifier CRD420251172600.